120
Participants
Start Date
May 30, 2019
Primary Completion Date
September 21, 2023
Study Completion Date
September 24, 2024
I-131-1095
Participants received up to 4 (8-week) cycles of I-131-1095: 100 mCi for the first dose. Subsequent dose(s) were reduced to 75 mCi for participants experiencing any dose-limiting toxicities. The third and fourth therapeutic doses could be reduced to 75 mCi on the basis of dosimetry assessment after administration of 10 mCi of I-131-1095 prior to the third dosing cycle. Participants also received the label dosage of enzalutamide once daily for up to 53 weeks.
Enzalutamide
Participants received the label dosage of enzalutamide once daily for up to 53 weeks.
SUNY Upstate Medical University, Syracuse
University of Pennsylvania, Philadelphia
Medstar Georgetown University Hospital, Washington D.C.
University of Maryland, Baltimore
University of Virginia Cancer Center, Charlottesville
Medical University of South Carolina, Charleston
University of Michigan Comprehensive Cancer Center, Ann Arbor
University of Iowa, Iowa City
The University of Chicago, Chicago
Washington University School of Medicine, St Louis
Tulane Medical School, New Orleans
University of Texas MD Anderson Cancer Center, Houston
VA Greater Los Angeles Healthcare System, Los Angeles
City of Hope, Duarte
Hoag Family Cancer Institute, Newport Beach
VA Palo Alto Healthcare System, Palo Alto
Virginia Mason Medical Center, Seattle
University of Washington - Seattle Cancer Care Alliance, Seattle
UCLA, Los Angeles
LifeSpan Cancer Institute, Providence
The Ottawa Hospital, Ottawa
London Health Sciences Centre, Toronto
University Health Network - Princess Margaret Cancer Centre, Toronto
Centre Hospitalier Del' Universite de Montreal, Montreal
Jewish General Hospital, Montreal
Centre Hospitalier Universitaire de Quebec, Québec
Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke
Progenics Pharmaceuticals, Inc.
INDUSTRY